Zosano Pharma
Zosano Pharma Corp (Form: 3/A, Received: 04/12/2018 16:07:27)
FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Aisling Capital IV, LP

2. Date of Event Requiring Statement (MM/DD/YYYY)
3/29/2018 

3. Issuer Name and Ticker or Trading Symbol

Zosano Pharma Corp [ZSAN]

(Last)        (First)        (Middle)

888 SEVENTH AVENUE, 12TH FLOOR, 

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

NEW YORK, NY 10106       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

4/9/2018 

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value of $0.0001   1600000   D   (1)  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The securities are directly held by Aisling Capital IV, LP ("Aisling"), and may be deemed to be benefically owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms.

Remarks:
This amendment is being filed solely to add Aisling GP and Aisling Partners as reporting persons and correct the addresses for Mr. Elms and Dr. Schiff. There are no other changes being made by this amendment.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Aisling Capital IV, LP
888 SEVENTH AVENUE, 12TH FLOOR
NEW YORK, NY 10106

X

Aisling Capital Partners IV, LP
888 SEVENTH AVE., 12TH FLOOR
NEW YORK, NY 10106

X

Aisling Capital Partners IV LLC
888 SEVENTH AVE., 12TH FLOOR
NEW YORK, NY 10106

X

ELMS STEVE
C/O AISLING CAPITAL MANAGEMENT LP
888 SEVENTH AVE., 12TH FLOOR
NEW YORK, NY 10106

X

SCHIFF ANDREW N
C/O AISLING CAPITAL MANAGEMENT LP
888 SEVENTH AVE., 12TH FLOOR
NEW YORK, NY 10106

X


Signatures
See Signatures on Exhibit 99.1 4/12/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
EXHIBIT 99.1

FORM 3 JOINT FILER INFORMATION
 
Names of Joint Filers:
 
Aisling Capital IV, LP
Steve Elms
Andrew N. Schiff, M.D.
 
Address of Joint Filers:
c/o Aisling Capital Management LP
888 Seventh Avenue, 12 th Floor
New York, NY 10106
 
Designated Filer: Aisling Capital IV, LP
Issuer and Ticker Symbol: Zosano Pharma Corporation [ZSAN]
Date of Event: March 29, 2018
Signatures of Joint Filers:

AISLING CAPITAL IV, LP
   
By:
Aisling Capital Partners IV, LP
 
General Partner
   
By:
Aisling Capital Partners IV LLC
 
General Partner
   
By:
/s/ Andrew Schiff
 
Name: Andrew Schiff
 
Title: Managing Member
   
 
AISLING CAPITAL PARTNERS IV, LP
   
By:
Aisling Capital Partners IV LLC
 
General Partner
   
By:
/s/ Andrew Schiff
 
Name: Andrew Schiff
 
Title: Managing Member
   
 
AISLING CAPITAL PARTNERS IV LLC
   
By:
/s/ Andrew Schiff
 
Name: Andrew Schiff
 
Title: Managing Member
   
 
/s/ Steve Elms
Steve Elms
 
/s/ Andrew Schiff
Andrew Schiff